Established in 1989 as the commercial arm of the Scottish Crop Research Institute, MRS assists UK agricultural and plant biotechology scientists develop their ideas into marketable products. Profits earned from its efforts are plowed back into the research institution. MRS labs offer pathogen testing, plant analysis, and consulting services. MRS works with companies interested in licensing technologies that the researchers use to breed high-quality varieties of potatoes, soft fruits, barley, and other agricultural products.

Cortex Pharmaceuticals develops drugs to treat neurodegenerative and psychiatric disorders. Its research focuses on the AMPA receptor, which facilitates communication between nerve cells; the firm's Ampakine compounds may enhance this receptor's activity. Its lead drug candidate is CX717, which it is developing for a number of indications including respiratory depression (a potentially fatal side effect of some anesthetics and post-surgical painkillers), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), and daytime sleepiness. The firm believes Ampakine drugs may also be helpful in treating a variety of other brain-related disorders, including depression, autism, and Huntington's disease.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Kyowa Hakko Kirin Co., Ltd., formerly KYOWA HAKKO KOGYO CO., LTD., is a Japan-based manufacturer that has five business segments. The Medical Product segment is engaged in the manufacture, sale and promotion of medical products for hospital use, as well as the provision of technologies for antibody drug creation, the development of candidate substances for new drugs and the supply of clinical test reagents. The Biochemical segment offers medical and industrial materials, mainly amino and nucleic acids, as well as healthcare items and products for agriculture and fishery uses. It also designs and constructs facilities. The Chemical Product segment provides solvents, plasticizers, materials for plasticizers and functional products, among others. Its Food segment supplies seasonings, materials for confectionery and bread making, processed food products and others. The Others segment is involved in the wholesale and distribution businesses, as well as the provision of industrial alcohol.

Bayhill Therapeutics knows that some immune responses are just way out of line. The biopharmaceutical developer is designing vaccines to eliminate problematic immune responses and restore the immune system to its normal state, known as "tolerance." Its product candidate BHT-3009 is being studied in clinical trials as a treatment for multiple sclerosis while its other leading candidate BHT-3021 is in clinical trials for the treatment of type 1 diabetes. The company's pre-clinical candidate, BHT-3034 is being developed as a treatment for myasthenia gravis, an autoimmune disease that causes interruption in the transmission of nerve impulses to muscles.

Grifols, Inc. company provides products and services through three primary divisions: bioscience, diagnostic, and hospital. The bioscience division processes plasma from the company's collection centers into therapeutic derivative products such as coagulation factors and liver dialysis products. Its diagnostic division makes reagents and testing devices and instruments for laboratories, including blood bags, separators, incubators, and refrigerators. Grifols provides equipment, software, nutritional products, and IV preparations for hospitals and pharmacies through its hospital division. The company operates nationwide and is a subsidiary of Spain-based Grifols, S.A.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Arnet Pharmaceutical manufactures private-label nutritional supplements. Arnet Pharmaceutical Corp. products range from daily vitamins and herbal extracts to minerals and amino acids. The company's capabilities include making tablet, capsule, powder, and chewable products. As a contract manufacturer, Arnet will work from customer-provided formulations or formulate products themselves. It also produces blended products such as Osteoporex, a calcium blend to address osteoporosis, and Gluthatione, an antioxidant supplement to increases energy and reduces stress. Founded in 1972, Arnet's customers span across more than 50 countries.

CXR Biosciences Ltd. company was founded in 2001 and is based in Dundee, the United Kingdom. CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug/drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The company also offers mechanistic toxicology, collaborative research, and microarray services. In addition, it provides various preclinical screening systems that include Hepatic Reductase Null, which is used for determining the role of hepatic P450 metabolism in drug disposition; ToxReporter Mice for the mechanistic assessment of potential toxic effects in vivo; antioxidant response elements; ToxReporter cell lines for drug safety screening; and nuclear hormone receptor transactivation assays. Further, the company licenses its products.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.